周洲 副教授 (硕士生导师)

周洲  副教授  (硕士生导师)    

单位：四川大学华西药学院药剂系

通讯地址：成都市人民南路三段17号四川大学华西药学院

E-mail: zhou_zhou610@163.com

简历

2005-2009  中山大学药学院，获理学学士学位

2009-2015  四川大学华西药学院，获药剂学博士学位

2015-　　 四川大学华西药学院药剂系任讲师、副教授

2018-2019   美国犹他大学药学院访问学者

研究方向

靶向给药系统的构建及其作用机制研究

主要研究课题

1. 国家自然科学基金委员会，青年基金项目，81603042，“一靶多效”的肿瘤细胞线粒体内膜靶向的HPMA聚合物交联胶束的构建与机制研究，2017至2019，主持。

2. 四川省科技厅，重点研发项目，2018SZ0032，可靶向肿瘤细胞和肿瘤相关巨噬细胞的复合靶向递药系统研究，2018至2019，主持。

3. 四川大学青年教师启动基金，2016SCU11008，具有溶酶体逃逸和细胞核靶向双功能的胶束给药系统的研究，2016至2017，主持。

代表性论著

1. Yuan Yao, Jing Tao, Jiayan Lyu, Cheng Chen, Yuan Huang, and Zhou Zhou*. Enhance Mitochondrial Damage by Nuclear Export Inhibition to Suppress Tumor Growth and Metastasis with Increased Antitumor Properties of Macrophages. ACS Appl. Mater. Interfaces 2023, 15, 20774−20787.

2. Chaohui Luo, Minglu Zhou, Cheng Chen, Shujie Li, Qiuyi Li, Yuan Huang, Zhou Zhou*. A liposome-based combination strategy using doxorubicin and a PI3K inhibitor efficiently inhibits pre-metastatic initiation by acting on both tumor cells and tumor-associated macrophages, Nanoscale, 2022, 14(12): 4573-4587.

3. Jiatao Yang, Qiuyi Li, Rui Zhou, Minglu Zhou, Xi Lin, Yucheng Xiang, Dandan Xie, Yuan Huang and Zhou Zhou*. Combination of mitochondria targeting doxorubicin with Bcl-2 function-converting peptide NuBCP-9 for synergistic breast cancer metastasis inhibition. Journal of Materials Chemistry B, 2021, 9(5): 1336-1350.

4. Jiatao Yang, Qiuyi Li, Minglu Zhou, Xiang Li, Yuan Huang, Nan Yang*, Zhou Zhou*. Concurrent impairment of nucleus and mitochondria for synergistic inhibition of cancer metastasis. International Journal of Pharmaceutics, 2021, 608: 121077.

5. Xiang Li^#, Zhou Zhou^#, Rui Zhou, Jiatao Yang, Minglu Zhou, Qiuyi Li, Lian Li, Yuan Huang*. Stimuli-Responsive Nanoparticles Combining Photodynamic Therapy and Mitochondria Disruption Suppressed Tumor Metastasis. Advanced Materials Interfaces, 2021: 2002200.

6. Qiuyi Li, Jiatao Yang, Cheng Chen, Xi Lin, Minglu Zhou, Zhou Zhou*, Yuan Huang*. A novel mitochondrial targeted hybrid peptide modified HPMA copolymers for breast cancer metastasis suppression. Journal of Controlled Release, 2020, 325: 38-51.

7. Yuanyuan Liu^#, Zhou Zhou^#, Xi Lin, Xiaofeng Xiong, Rui Zhou, Minglu Zhou, Yuan Huang*. Enhanced Reactive Oxygen Species Generation by MitochondriaTargeting of Anticancer Drug To Overcome Tumor Multidrug Resistance. Biomacromolecules, 2019, 20(10): 3755-3766.

8. Yanxi Liu, Qiuyi Li, Xiaofeng Xiong, Zhou Zhou*. Improved mitochondrial targeting effect of HPMA copolymer by SS20 peptide mediation and nonendocytosis pathway. Journal of Peptide Science, 2019, 25(2): e3144.

9. Yanxi Liu, Qiuyi Li, Xiaofeng Xiong, Yuan Huang and Zhou Zhou*. Mitochondria targeting and cell-penetrating peptides-co-modified HPMA copolymers for enhancing therapeutic efficacy of α-tocopheryl succinate. Journal of Materials, Chemistry B, 2018, 6(46): 7674-7683.

10. Yanxi Liu, Qiuyi Li, Xiaofeng Xiong, Yuan Huang and Zhou Zhou*. Enhanced cellular uptake by non-endocytic pathway for tumor therapy. Journal of Materials Chemistry B, 2018, 6(45): 7411-7419.

11. Fengling Wang, Lian Li, Wei Sun, Lijia Li, Yuanyuan Liu, Yuan Huang, Zhou Zhou*. A novel alpha(V) beta(3) ligand-modified HPMA copolymers for anticancer drug delivery. Journal of Drug Targeting, 2018, 26(3): 231-241.

12. Zhou Zhou, YanXi Liu, Lei Wu, Lian Li and Yuan Huang*. Enhanced nuclear delivery of anti-cancer drugs using micelles containing releasable membrane fusion peptide and nuclear-targeting retinoic acid. Journal of Materials Chemistry B, 2017, 5(34): 7175-7185.

13. Manling Tang, Minglu Zhou, Yuan Huang, Jiaju Zhong, Zhou Zhou* and Kui Luo*. Dual-sensitive and biodegradable core-crosslinked HPMA copolymer-doxorubicin conjugate-based nanoparticles for cancer therapy. Polymer Chemistry, 2017, 8(15): 2370-2380.